BIT 3.33% 3.1¢ biotron limited

On the brink of something historic.., page-2

  1. 499 Posts.
    lightbulb Created with Sketch. 273
    What I like is it is not really disruptive for Big pharma business model.

    It doesn't interrupt their Revenue model ...so long as they partner with BIT.


    Can they afford not to partner to BIT?


    This is an opportunity for a rival to take market share in the lucrative HIV market.








 
watchlist Created with Sketch. Add BIT (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.